CA3105795C - Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors - Google Patents
Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors Download PDFInfo
- Publication number
- CA3105795C CA3105795C CA3105795A CA3105795A CA3105795C CA 3105795 C CA3105795 C CA 3105795C CA 3105795 A CA3105795 A CA 3105795A CA 3105795 A CA3105795 A CA 3105795A CA 3105795 C CA3105795 C CA 3105795C
- Authority
- CA
- Canada
- Prior art keywords
- inhibitors
- antagonists
- receptor
- modulators
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718273P | 2018-08-13 | 2018-08-13 | |
| US62/718,273 | 2018-08-13 | ||
| PCT/US2019/046380 WO2020036979A1 (en) | 2018-08-13 | 2019-08-13 | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3105795A1 CA3105795A1 (en) | 2020-02-20 |
| CA3105795C true CA3105795C (en) | 2024-01-16 |
Family
ID=67777432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3105795A Active CA3105795C (en) | 2018-08-13 | 2019-08-13 | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11572362B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3837012A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7169429B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102660255B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112566697B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019321424B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3105795C (cg-RX-API-DMAC7.html) |
| TW (1) | TWI797366B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020036979A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| US9624246B2 (en) | 2015-02-06 | 2017-04-18 | Merck Patent Gmbh | Pyridazinone macrocycles as IRAK inhibitors and uses thereof |
| EP3313840B1 (en) | 2015-06-24 | 2019-07-24 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| US10618903B2 (en) * | 2015-06-24 | 2020-04-14 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| TW202340194A (zh) * | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
-
2019
- 2019-08-13 TW TW108128802A patent/TWI797366B/zh active
- 2019-08-13 US US16/539,753 patent/US11572362B2/en active Active
- 2019-08-13 CA CA3105795A patent/CA3105795C/en active Active
- 2019-08-13 KR KR1020217007282A patent/KR102660255B1/ko active Active
- 2019-08-13 WO PCT/US2019/046380 patent/WO2020036979A1/en not_active Ceased
- 2019-08-13 JP JP2021507445A patent/JP7169429B2/ja active Active
- 2019-08-13 CN CN201980053454.6A patent/CN112566697B/zh active Active
- 2019-08-13 EP EP19759815.4A patent/EP3837012A1/en active Pending
- 2019-08-13 AU AU2019321424A patent/AU2019321424B2/en active Active
-
2022
- 2022-06-22 AU AU2022204399A patent/AU2022204399A1/en not_active Abandoned
- 2022-07-06 JP JP2022109092A patent/JP2022130716A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3105795A1 (en) | 2020-02-20 |
| EP3837012A1 (en) | 2021-06-23 |
| TWI797366B (zh) | 2023-04-01 |
| US20200071333A1 (en) | 2020-03-05 |
| AU2019321424B2 (en) | 2022-07-14 |
| JP7169429B2 (ja) | 2022-11-10 |
| AU2022204399A1 (en) | 2022-07-14 |
| WO2020036979A1 (en) | 2020-02-20 |
| KR20210044819A (ko) | 2021-04-23 |
| TW202021966A (zh) | 2020-06-16 |
| CN112566697B (zh) | 2024-04-16 |
| CN112566697A (zh) | 2021-03-26 |
| JP2022130716A (ja) | 2022-09-06 |
| JP2021535904A (ja) | 2021-12-23 |
| KR102660255B1 (ko) | 2024-04-25 |
| AU2019321424A1 (en) | 2021-01-28 |
| US11572362B2 (en) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201840567A (zh) | 吡咯并[1,2-b]嗒𠯤衍生物 | |
| ES2981798T3 (es) | Derivados de pirrolo[1,2-b] piridazina | |
| CA3105795C (en) | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors | |
| JP2023002695A (ja) | IRAK4阻害剤としてのピロロ[1,2-b]ピリダジン誘導体 | |
| AU2024203567B2 (en) | Pyrrolo[1,2-b] pyridazine derivatives | |
| HK40113639A (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| HK40052653B (en) | Pyrrolo[1,2-b] pyridazine derivatives | |
| HK40052653A (en) | Pyrrolo[1,2-b] pyridazine derivatives | |
| EA049327B1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА | |
| EA045296B1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210105 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250625 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250625 |